TrovaGene, Inc. (NASDAQ:TROV)

CAPS Rating: 2 out of 5

Results 1 - 3 of 3

Recs

0
Member Avatar nancytroi (< 20) Submitted: 10/7/2013 11:40:15 AM : Outperform Start Price: $7.39 TROV Score: -42.87

New Diagnostic tests for cancer.

Recs

0
Member Avatar ctcarrigan33 (52.03) Submitted: 7/23/2013 12:14:52 PM : Outperform Start Price: $8.42 TROV Score: -50.44

Cheaper than blood tests or traditional tests, and their validation tests of the technology have been positive thus far

Recs

0
Member Avatar Becker2011 (63.20) Submitted: 5/14/2013 10:15:08 AM : Outperform Start Price: $6.66 TROV Score: -37.90

This is biotech at an early research stage, but a very interesting play. Imagine screening for various diseases and cancer all with a simple urine test. No more blood work and no more needles.

As with all biotechs -- if* they get this right, they are gonna make a lot of money

Results 1 - 3 of 3

Featured Broker Partners


Advertisement